• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 25-NSE filed by EQRx Inc.

    11/9/23 10:12:04 AM ET
    $EQRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $EQRX alert in real time by email
    NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.
    UNITED STATES
    OMB APPROVAL
    OMB Number: 3235-0080
    Expires: March 31, 2018
    Estimated average burden
    hours per response: 1.7
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM 25
    NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
    UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.
    Commission File Number 001-40312
    Issuer: EQRx, Inc.
    Exchange: Nasdaq Stock Market LLC
    (Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)
    Address: c/o Corvex Management LP
    667 Madison Avenue
    New York NEW YORK 10065
    Telephone number: 212-474-6724
    (Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)
    Common Stock, Warrant
    (Description of class of securities)
    Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:
    17 CFR 240.12d2-2(a)(1)
    17 CFR 240.12d2-2(a)(2)
    17 CFR 240.12d2-2(a)(3)
    17 CFR 240.12d2-2(a)(4)
    Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. 1
    Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.
    Pursuant to the requirements fo the Securities Exchange Act of 1934, Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.
    2023-11-09 By Tara Petta Director
    Date Name Title
    1 Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $EQRX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EQRX

    DatePrice TargetRatingAnalyst
    11/14/2022Neutral → Underweight
    JP Morgan
    11/11/2022$8.00 → $5.00Buy → Neutral
    Goldman
    11/11/2022$5.60 → $3.20Buy → Hold
    Jefferies
    8/16/2022$5.50Neutral
    JP Morgan
    6/13/2022$8.00Buy
    Goldman
    4/22/2022Outperform
    Cowen
    3/18/2022$5.60Buy
    Jefferies
    More analyst ratings

    $EQRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • EQRx downgraded by JP Morgan

      JP Morgan downgraded EQRx from Neutral to Underweight

      11/14/22 7:36:09 AM ET
      $EQRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EQRx downgraded by Goldman with a new price target

      Goldman downgraded EQRx from Buy to Neutral and set a new price target of $5.00 from $8.00 previously

      11/11/22 9:09:51 AM ET
      $EQRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EQRx downgraded by Jefferies with a new price target

      Jefferies downgraded EQRx from Buy to Hold and set a new price target of $3.20 from $5.60 previously

      11/11/22 7:14:21 AM ET
      $EQRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EQRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Nallicheri Melanie returned 10,157,393 shares to the company and exercised 626,999 shares at a strike of $2.21, closing all direct ownership in the company (SEC Form 4)

      4 - EQRx, Inc. (0001843762) (Issuer)

      11/9/23 4:27:28 PM ET
      $EQRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Merksamer Samuel J.

      4 - EQRx, Inc. (0001843762) (Issuer)

      11/9/23 4:18:02 PM ET
      $EQRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Berns Paul L returned 627,000 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - EQRx, Inc. (0001843762) (Issuer)

      11/9/23 4:18:04 PM ET
      $EQRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EQRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Lifshitz Law PLLC Announces Investigations of EQRX, RVMD, NEWR, and RETA

      NEW YORK, Aug. 05, 2023 (GLOBE NEWSWIRE) -- EQRx, Inc. (NASDAQ:EQRX) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of EQRX to Revolution Medicines, Inc. Under the terms of the proposed merger, EQRX shareholders will receive the number of shares of Revolution Medicines, Inc. stock equal to the sum of ~7.69M Revolution Medicines, Inc. shares plus a number of shares equal to $870M divided by a price that is a 6% discount to the 5-day volume-weighted average Revolution Medicines Inc. share price measured in close proximity to the stockholder vote. If you are an EQRX investor, and would like additional information abo

      8/5/23 8:13:00 PM ET
      $EQRX
      $NEWR
      $RETA
      $RVMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Computer Software: Prepackaged Software
      Technology
    • Revolution Medicines, Inc. to Acquire EQRx, Inc. in All-Stock Transaction to Gain More Than $1 Billion in Additional Capital

      Revolution Medicines Expects to Conduct Late-Stage Development of RAS(ON) Inhibitor Drug Candidate Pipeline Supported by Fortified Balance Sheet Agreement is the Result of a Rigorous Process Conducted by Independent Transaction Committee of EQRx Board to Consider Strategic Alternatives to Maximize Value for EQRx Stockholders Transaction Expected to Close in November 2023 REDWOOD CITY, Calif. and CAMBRIDGE, Mass., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. ("Revolution Medicines" or the "Company") (NASDAQ:RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, and EQRx, Inc. ("EQRx") (NASDAQ:EQRX) today announced a definitive agr

      8/1/23 7:00:00 AM ET
      $EQRX
      $RVMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • EQRx Resets to Focus on Clinically Differentiated Medicines, Leveraging $1.3 Billion Cash Position; Reports First Quarter 2023 Financial Results

      Company to utilize significant scale of capital and team to advance a pipeline of clinically differentiated, high-value therapiesPrioritizing development of lerociclib (CDK 4/6 inhibitor); initiated Phase 3 trial in first-line advanced endometrial cancer; enrollment in Phase 2 trial in first- and second-line advanced breast cancer near completion, providing a foundation for future combination development opportunitiesSeeking commercialization partnerships for aumolertinib (third-generation EGFR inhibitor)Terminating license agreements for sugemalimab (anti-PD-L1 antibody), nofazinlimab (anti-PD-1 antibody) and EQ121 (JAK-1 inhibitor)$1.3 billion in cash, cash equivalents and short-term inves

      5/8/23 4:01:57 PM ET
      $EQRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EQRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by EQRx Inc. (Amendment)

      SC 13G/A - EQRx, Inc. (0001843762) (Subject)

      11/17/23 4:23:37 PM ET
      $EQRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by EQRx Inc. (Amendment)

      SC 13D/A - EQRx, Inc. (0001843762) (Subject)

      11/17/23 6:00:34 AM ET
      $EQRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by EQRx Inc. (Amendment)

      SC 13D/A - EQRx, Inc. (0001843762) (Subject)

      11/15/23 5:27:53 PM ET
      $EQRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EQRX
    Financials

    Live finance-specific insights

    See more
    • Revolution Medicines, Inc. to Acquire EQRx, Inc. in All-Stock Transaction to Gain More Than $1 Billion in Additional Capital

      Revolution Medicines Expects to Conduct Late-Stage Development of RAS(ON) Inhibitor Drug Candidate Pipeline Supported by Fortified Balance Sheet Agreement is the Result of a Rigorous Process Conducted by Independent Transaction Committee of EQRx Board to Consider Strategic Alternatives to Maximize Value for EQRx Stockholders Transaction Expected to Close in November 2023 REDWOOD CITY, Calif. and CAMBRIDGE, Mass., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. ("Revolution Medicines" or the "Company") (NASDAQ:RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, and EQRx, Inc. ("EQRx") (NASDAQ:EQRX) today announced a definitive agr

      8/1/23 7:00:00 AM ET
      $EQRX
      $RVMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • EQRx Resets to Focus on Clinically Differentiated Medicines, Leveraging $1.3 Billion Cash Position; Reports First Quarter 2023 Financial Results

      Company to utilize significant scale of capital and team to advance a pipeline of clinically differentiated, high-value therapiesPrioritizing development of lerociclib (CDK 4/6 inhibitor); initiated Phase 3 trial in first-line advanced endometrial cancer; enrollment in Phase 2 trial in first- and second-line advanced breast cancer near completion, providing a foundation for future combination development opportunitiesSeeking commercialization partnerships for aumolertinib (third-generation EGFR inhibitor)Terminating license agreements for sugemalimab (anti-PD-L1 antibody), nofazinlimab (anti-PD-1 antibody) and EQ121 (JAK-1 inhibitor)$1.3 billion in cash, cash equivalents and short-term inves

      5/8/23 4:01:57 PM ET
      $EQRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EQRx to Hold First Quarter 2023 Financial Results Conference Call on Monday, May 8, 2023

      CAMBRIDGE, Mass., April 27, 2023 (GLOBE NEWSWIRE) -- EQRx, Inc. (NASDAQ:EQRX), a new type of pharmaceutical company committed to developing and expanding access to innovative medicines for some of the most prevalent disease areas, including cancer and immune-inflammatory conditions, today announced it will host a conference call and webcast on Monday, May 8, 2023, at 4:30 p.m. ET to report its first quarter 2023 financial results and provide a business update. A live webcast of the call will be available on the "Investor Relations" page of the Company's website at https://investors.eqrx.com/news-events/events-presentations. To access the call by phone, participants should visit this link

      4/27/23 8:00:34 AM ET
      $EQRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EQRX
    SEC Filings

    See more
    • SEC Form 15-12G filed by EQRx Inc.

      15-12G - EQRx, Inc. (0001843762) (Filer)

      11/20/23 4:00:52 PM ET
      $EQRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by EQRx Inc.

      EFFECT - EQRx, Inc. (0001843762) (Filer)

      11/20/23 12:15:18 AM ET
      $EQRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by EQRx Inc.

      EFFECT - EQRx, Inc. (0001843762) (Filer)

      11/20/23 12:15:12 AM ET
      $EQRX
      Biotechnology: Pharmaceutical Preparations
      Health Care